ClinicalTrials.gg
CompletedNCT02898454SINUS-52Updated Oct 23, 2019Results posted

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

A Phase 3 interventional study of Dupilumab SAR231893 (REGN668) and Placebo in Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), sponsored by Sanofi. Completed at 123 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-23.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
448
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing dupilumab in Nasal Polyps — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Nasal Polyps.

Enrollment
2nd of 16
448 · median 45
Started
2016
with 1 other
Phase 3
4 of 16
none open now
Registered
2nd of 16
by date
Lead sponsor
5 of 16
Sanofi

Among the 16 studies testing dupilumab in Nasal Polyps, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 3, and was the 2nd registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

4 of the 16 studies testing dupilumab in Nasal Polyps are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing dupilumab in Nasal Polyps, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab 300 mg every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion (NC)/obstruction severity and endoscopic nasal polyp score (NPS) in participants with bilateral nasal polyps (NP). In addition for Japanese participants, reduction in computed tomography (CT) scan opacification of the sinuses was a co-primary objective.

Secondary Objectives:

  • To evaluate the efficacy of dupilumab in improving total symptoms score.
  • To evaluate the efficacy of dupilumab in improving sense of smell.
  • To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (primary objective for Japanese participants).
  • To evaluate ability of dupilumab in reducing proportion of participants who required treatment with systemic corticosteroids (SCS) or surgery for NP.
  • To evaluate the effect of dupilumab on participant reported outcomes and health related quality of life.
  • To evaluate the efficacy of dupilumab 300 mg q2w up to Week 52.
  • To evaluate the efficacy of dupilumab 300 mg q2w up to Week 24 followed by 300 mg every 4 weeks (q4w) up to Week 52.
  • To evaluate the effect of dupilumab in the subgroups of participants with prior surgery and comorbid asthma including non-steroid anti-inflammatory drug exacerbated respiratory disease.
  • To evaluate the safety of dupilumab in participants with bilateral NP.
  • To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatment emergent anti-drug antibodies.
Read the detailed description

The total study duration per participant was up to 68 weeks that consisted of a 4-weeks run-in period, 52-weeks treatment period, and a 12-weeks post treatment period.

03

Conditions studied

  • Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with bilateral sino-nasal polyposis that despite prior treatment with SCS anytime within the past 2 years; and/or had a medical /intolerance to SCS; and/or had prior surgery for NP at the screening visit, had:
  • An endoscopic bilateral NPS at Visit 1 (V1) of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).
  • Ongoing symptoms (for at least 8 weeks before V1) of NC/blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Participants \<18 years of age.
  • Participant who had been previously treated in dupilumab studies.
  • Participant who had taken:

    • Biologic therapy/ systemic to treat inflammatory disease or disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever was longer.
    • Any experimental monoclonal antibody within 5 half-lives or within 6 months before V1 if the half-life was unknown.
    • Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.
    • Participants who received leukotriene antagonists/modifiers at V1 unless they were on a continuous treatment for at least 30 days prior to V1.
  • Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.
  • Participants who underwent any and/or sinus surgery (including polypectomy) within 6 months before V1.
  • Participants who had a sino-nasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.
  • Participants with conditions/concomitant diseases making them non evaluable at V1 or for the primary efficacy endpoint such as:

    • Antrochoanal polyps,
    • Nasal septal deviation that would occlude at least one nostril,
    • Acute sinusitis, nasal infection or upper respiratory infection,
    • Ongoing rhinitis medicamentosa,
    • Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis),Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, concomitant cystic fibrosis,
    • Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.
  • Participants with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).
  • Participants with forced expiratory volume 50% or less (of predicted normal).
  • Participants who received concomitant treatment prohibited in the study.
  • Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit.
  • Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.
  • History of (HIV) infection or positive HIV serology at screening.
  • Positive with surface antigen or antibody at the screening visit.
  • Active chronic or acute infection requiring systemic treatment within 2 weeks before the baseline visit.
  • Known or suspected history of immunosuppression.
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
  • Women unwilling to use adequate , if of and sexually active.

The above information was not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
448 participants (actual)

Study arms

  • Experimental
    Dupilumab 300 mg q2w

    Dupilumab 300 mg subcutaneous (SC) injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.

    Drug: Dupilumab SAR231893 (REGN668) · Drug: Mometasone furoate nasal spray

  • Experimental
    Dupilumab 300 mg q2w then q4w

    Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 and then 300 mg q4w until Week 52 added to background therapy of intranasal MFNS at stable dose. After Week 24, Dupilumab administration was alternated with matched placebo injection every other week up to Week 50.

    Drug: Dupilumab SAR231893 (REGN668) · Drug: Placebo · Drug: Mometasone furoate nasal spray

  • Placebo comparator
    Placebo

    Placebo (for dupilumab), 1 SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.

    Drug: Placebo · Drug: Mometasone furoate nasal spray

Interventions

  • Pharmaceutical form: Solution Route of administration: Subcutaneous

  • DrugPlacebo

    Pharmaceutical form: Solution Route of administration: Subcutaneous

  • Pharmaceutical form: Suspension Route of administration: Intranasal

    Also known as: NASONEX®

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score

    NC symptom severity was assessed by the participants on a daily basis from visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Least squares (LS) means and standard error (SE) were obtained from Analysis of covariance (ANCOVA) model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  2. Change From Baseline at Week 24 in Nasal Polyp Score

    NPS: sum of right, left nostril scores, evaluated by nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 = no polyps to 4 = large polyps causing complete obstruction of inferior nasal cavity; lower score = smaller sized polyps. Total NPS: sum of right and left nostril scores, ranges from 0 (no polyps) to 8 (large polyps), higher score = more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay (LMK) Score

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. NOTE: For Japan regulatory submission only, this endpoint is not included as a secondary outcome measure and is instead one of the co-primary outcome measures. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  2. Change From Baseline at Week 24 in Total Symptom Score (TSS)

    The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  3. Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score

    The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  4. Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily

    The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  5. Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores

    The SNOT-22 is a validated questionnaire was used to assess the impact of chronic rhinosinusitis phenotype with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  6. Change From Baseline at Week 52 in Nasal Polyp Score

    NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

    Time frame: Baseline, Week 52

  7. Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score

    NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

    Time frame: Baseline, Week 52

  8. Change From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores

    The SNOT-22 is a validated questionnaire that was used to assess the impact of CRSwNP on HRQoL. It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

    Time frame: Baseline, Week 52

  9. Rescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method

    Rescue treatment was defined as usage of systemic corticosteroids (SCS) or NP surgery (actual or planned) during the treatment period. Rescue treatment included: * SCS: betamethasone, deflazacort, dexamethasone, dexamethasone sodium phosphate, hydrocortisone, meprednisone, methylprednisolone, methylprednisolone sodium succinate, prednisolone, prednisolone sodium succinate, prednisone, stelamin, triamcinolone, and triamcinolone acetonide. * Sino-nasal surgery for nasal polyps when there was worsening of signs and/or symptoms during the study. Estimate of percentage of participants with event by Week 52 was obtained using Kaplan-Meier method.

    Time frame: Baseline up to 52 weeks

  10. Change From Baseline at Week 52 in Total Symptom Score

    The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  11. Change From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score

    The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  12. Change From Baseline at Week 52 in Severity of Decreased/Loss of Smell

    The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  13. Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  14. Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis

    The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?" The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  15. Change From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis

    The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?" The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  16. Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)

    NPIF evaluation represented a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute. Higher NPIF values were indicative of better nasal air flow. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  17. Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score

    Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  18. Change From Baseline at Week 52 in Rhinorrhea Daily Symptom Score

    Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  19. Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period

    SCS included: betamethasone, deflazacort, dexamethasone, dexamethasone sodium phosphate, hydrocortisone, meprednisone, methylprednisolone, methylprednisolone sodium succinate, prednisolone, prednisolone sodium succinate, prednisone, stelamin, triamcinolone, and triamcinolone acetonide. For every participant, the total dose was calculated as (prescribed total daily dose\*duration of SCS use). Then, mean of the total dose of 64 participants (placebo group), 17 participants (dupilumab 300 mg q2w then q4w) and 22 participants (dupilumab 300 mg q2w) was derived.

    Time frame: Baseline to Week 52

  20. Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant

    Rescue treatment was defined as usage of SCS or NP surgery (actual or planned) during the treatment period. SCS Rescue intake duration was defined as the duration (in days) from start of SCS rescue medication till the end of SCS rescue treatment.

    Time frame: Baseline to Week 52

  21. Changed From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  22. Change From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  23. Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) for Participants With Asthma

    ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment, asthma status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  24. Change From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma

    ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment, asthma status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  25. Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma

    NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  26. Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma

    NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  27. Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery

    NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  28. Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery

    NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.

    Time frame: Baseline, Week 52

  29. Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma

    NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  30. Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma

    NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

    Time frame: Baseline, Week 52

  31. Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery

    NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  32. Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery

    NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

    Time frame: Baseline, Week 52

  33. Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  34. Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

    Time frame: Baseline, Week 52

  35. Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  36. Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery

    The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.

    Time frame: Baseline, Week 52

  37. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation

    An Adverse Event (AE) was defined as any untoward medical occurrence that did not necessarily have to have a causal relationship with the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of drug until 84 days following the last administration of drug. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

    Time frame: Baseline up to 84 days after last dose of study drug (up to 64 weeks)

  38. Change From Baseline at Week 24 in European Quality of Life 5 Dimension Scale (EQ-5D) Visual Analog Scale Score

    The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable). All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

    Time frame: Baseline, Week 24

  39. Change From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score

    The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).

    Time frame: Baseline, Week 52

  40. Functional Dupilumab Concentration in Serum

    Time frame: Baseline, Week 2, Week 4, Week 16, Week 24, Week 40, End of treatment (Week 52), End of study (Week 64)

  41. Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA)

    ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as a positive response in the ADA assay post first dose, when baseline results are negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that is greater-than or equal to 4-fold over baseline titer levels, when baseline results are positive.

    Time frame: Baseline to Week 52

07

Results

Posted Oct 23, 2019

Participant flow

Study participants were involved in the study from 28 November 2016 to 16 November 2018 at 117 centers in 14 countries. A total of 806 participants were screened, of which 448 participants were enrolled and randomized to receive dupilumab 300 mg or placebo. A total of 358 participants had screen failures due to failure to meet inclusion criteria.

Participant flow — Overall Study
MilestonePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Started153145150
Intent-to-treat (itt) population153145150
Treated152145150
Safety population150148149
Completed136140144
Not completed1756
Withdrew: Adverse event412
Withdrew: Protocol violation101
Withdrew: Lack of efficacy410
Withdrew: Withdrawal by subject633
Withdrew: Lost to follow-up100
Withdrew: Did not met eligibility criteria100

Outcome measures

PrimaryChange From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score

NC symptom severity was assessed by the participants on a daily basis from visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Least squares (LS) means and standard error (SE) were obtained from Analysis of covariance (ANCOVA) model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score-0.38 ± 0.07-1.25 ± 0.06
Statistical analysis
  • Placebo vs Dupilumab 300 mg (24 Weeks Pooled Arm) · ANCOVA · p = <0.0001 · Ls mean difference: -0.87 · 95% CI -1.03 to -0.71
PrimaryChange From Baseline at Week 24 in Nasal Polyp Score

NPS: sum of right, left nostril scores, evaluated by nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 = no polyps to 4 = large polyps causing complete obstruction of inferior nasal cavity; lower score = smaller sized polyps. Total NPS: sum of right and left nostril scores, ranges from 0 (no polyps) to 8 (large polyps), higher score = more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Polyp Score
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Nasal Polyp Score0.10 ± 0.14-1.71 ± 0.11
Statistical analysis
  • Placebo vs Dupilumab 300 mg (24 Weeks Pooled Arm) · ANCOVA · p = <0.0001 · Ls mean difference: -1.80 · 95% CI -2.10 to -1.51
SecondaryChange From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay (LMK) Score

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. NOTE: For Japan regulatory submission only, this endpoint is not included as a secondary outcome measure and is instead one of the co-primary outcome measures. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay (LMK) Score
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay (LMK) Score-0.09 ± 0.31-5.21 ± 0.24
Statistical analysis
  • Placebo vs Dupilumab 300 mg (24 Weeks Pooled Arm) · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -5.13 · 95% CI -5.80 to -4.46
SecondaryChange From Baseline at Week 24 in Total Symptom Score (TSS)

The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Total Symptom Score (TSS)
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Total Symptom Score (TSS)-1.00 ± 0.20-3.45 ± 0.15
Statistical analysis
  • Placebo vs Dupilumab 300 mg (24 Weeks Pooled Arm) · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -2.44 · 95% CI -2.87 to -2.02
SecondaryChange From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score

The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score-0.81 ± 0.719.71 ± 0.56
Statistical analysis
  • Placebo vs Dupilumab 300 mg (24 Weeks Pooled Arm) · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 10.52 · 95% CI 8.98 to 12.07
SecondaryChange From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily

The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily-0.23 ± 0.08-1.21 ± 0.06
Statistical analysis
  • Placebo vs Dupilumab 300 mg (24 Weeks Pooled Arm) · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -0.98 · 95% CI -1.15 to -0.81
SecondaryChange From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores

The SNOT-22 is a validated questionnaire was used to assess the impact of chronic rhinosinusitis phenotype with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores-10.40 ± 1.61-27.77 ± 1.26
Statistical analysis
  • Placebo vs Dupilumab 300 mg (24 Weeks Pooled Arm) · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -17.36 · 95% CI -20.87 to -13.85
SecondaryChange From Baseline at Week 52 in Nasal Polyp Score

NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Nasal Polyp Score
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Nasal Polyp Score0.16 ± 0.15-2.05 ± 0.15-2.24 ± 0.15
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w Then q4w · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -2.21 · 95% CI -2.59 to -1.83Dupilumab 300 mg q2w then q4w vs. Placebo
  • Placebo vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -2.41 · 95% CI -2.78 to -2.03Dupilumab 300 mg q2w vs. Placebo
SecondaryChange From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score

NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score-0.37 ± 0.08-1.48 ± 0.08-1.36 ± 0.07
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w Then q4w · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -1.11 · 95% CI -1.30 to -0.92Dupilumab 300 mg q2w then q4w vs. Placebo
  • Placebo vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -0.99 · 95% CI -1.18 to -0.80Dupilumab 300 mg q2w vs. Placebo
SecondaryChange From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores

The SNOT-22 is a validated questionnaire that was used to assess the impact of CRSwNP on HRQoL. It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores-9.06 ± 1.61-30.42 ± 1.65-29.79 ± 1.64
Statistical analysis
  • Placebo vs Dupilumab 300 mg q2w Then q4w · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -21.36 · 95% CI -25.45 to -17.27Dupilumab 300 mg q2w then q4w vs. Placebo
  • Placebo vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -20.73 · 95% CI -24.81 to -16.65Dupilumab 300 mg q2w vs. Placebo
SecondaryRescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method

Rescue treatment was defined as usage of systemic corticosteroids (SCS) or NP surgery (actual or planned) during the treatment period. Rescue treatment included: * SCS: betamethasone, deflazacort, dexamethasone, dexamethasone sodium phosphate, hydrocortisone, meprednisone, methylprednisolone, methylprednisolone sodium succinate, prednisolone, prednisolone sodium succinate, prednisone, stelamin, triamcinolone, and triamcinolone acetonide. * Sino-nasal surgery for nasal polyps when there was worsening of signs and/or symptoms during the study. Estimate of percentage of participants with event by Week 52 was obtained using Kaplan-Meier method.

Time frame:
Baseline up to 52 weeks
Reported as:
Number · percentage of participants with event
Rescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method
percentage of participants with eventPlaceboDupilumab 300 mg (Pooled Arm)
SCS treatment42.5 (34.5 to 50.2)13.1 (9.0 to 18.0)
NP surgery28.3 (21.2 to 35.7)5.5 (2.9 to 9.4)
SecondaryChange From Baseline at Week 52 in Total Symptom Score

The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Total Symptom Score
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Total Symptom Score-0.93 ± 0.20-4.17 ± 0.20-3.79 ± 0.20
SecondaryChange From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score

The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score-0.78 ± 0.719.99 ± 0.739.53 ± 0.72
SecondaryChange From Baseline at Week 52 in Severity of Decreased/Loss of Smell

The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Severity of Decreased/Loss of Smell
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Severity of Decreased/Loss of Smell-0.18 ± 0.09-1.49 ± 0.09-1.29 ± 0.08
SecondaryChange From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score0.11 ± 0.37-5.60 ± 0.37-6.83 ± 0.37
SecondaryChange From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis

The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?" The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · centimeters
Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis
centimetersPlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis-1.39 ± 0.24-4.32 ± 0.19
SecondaryChange From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis

The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?" The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · centimeters
Change From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis
centimetersPlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis-0.93 ± 0.26-4.39 ± 0.26-4.74 ± 0.26
SecondaryChange From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)

NPIF evaluation represented a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute. Higher NPIF values were indicative of better nasal air flow. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · liters per minute
Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)
liters per minutePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)18.65 ± 3.9555.29 ± 3.08
SecondaryChange From Baseline at Week 24 in Rhinorrhea Daily Symptom Score

Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score-0.40 ± 0.07-0.99 ± 0.05
SecondaryChange From Baseline at Week 52 in Rhinorrhea Daily Symptom Score

Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Rhinorrhea Daily Symptom Score
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Rhinorrhea Daily Symptom Score-0.35 ± 0.07-1.19 ± 0.07-1.15 ± 0.07
SecondaryMean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period

SCS included: betamethasone, deflazacort, dexamethasone, dexamethasone sodium phosphate, hydrocortisone, meprednisone, methylprednisolone, methylprednisolone sodium succinate, prednisolone, prednisolone sodium succinate, prednisone, stelamin, triamcinolone, and triamcinolone acetonide. For every participant, the total dose was calculated as (prescribed total daily dose\*duration of SCS use). Then, mean of the total dose of 64 participants (placebo group), 17 participants (dupilumab 300 mg q2w then q4w) and 22 participants (dupilumab 300 mg q2w) was derived.

Time frame:
Baseline to Week 52
Reported as:
Mean · milligrams
Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period
milligramsPlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period547.56 ± 665.40282.38 ± 243.15389.68 ± 502.61
SecondaryTotal Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant

Rescue treatment was defined as usage of SCS or NP surgery (actual or planned) during the treatment period. SCS Rescue intake duration was defined as the duration (in days) from start of SCS rescue medication till the end of SCS rescue treatment.

Time frame:
Baseline to Week 52
Reported as:
Mean · days
Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant
daysPlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant19.58 ± 17.6710.71 ± 9.0023.23 ± 55.23
SecondaryChanged From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · liters
Changed From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma
litersPlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Changed From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma-0.05 ± 0.050.17 ± 0.04
SecondaryChange From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · liters
Change From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma
litersPlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma-0.18 ± 0.050.10 ± 0.050.06 ± 0.05
SecondaryChange From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) for Participants With Asthma

ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment, asthma status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) for Participants With Asthma
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) for Participants With Asthma0.08 ± 0.09-0.78 ± 0.07
SecondaryChange From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma

ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment, asthma status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma0.12 ± 0.10-0.76 ± 0.10-0.83 ± 0.10
SecondaryChange From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma

NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma-0.39 ± 0.09-1.36 ± 0.07
SecondaryChange From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma

NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma-0.34 ± 0.09-1.51 ± 0.09-1.44 ± 0.09
SecondaryChange From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery

NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery-0.27 ± 0.10-1.30 ± 0.08
SecondaryChange From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery

NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery-0.25 ± 0.10-1.54 ± 0.10-1.35 ± 0.09
SecondaryChange From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma

NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma0.13 ± 0.17-1.88 ± 0.13
SecondaryChange From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma

NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma0.29 ± 0.20-2.25 ± 0.20-2.34 ± 0.20
SecondaryChange From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery

NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery0.22 ± 0.19-1.73 ± 0.15
SecondaryChange From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery

NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery0.21 ± 0.21-2.22 ± 0.22-2.56 ± 0.21
SecondaryChange From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma-0.33 ± 0.40-5.86 ± 0.31
SecondaryChange From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma-0.20 ± 0.46-6.23 ± 0.45-7.22 ± 0.47
SecondaryChange From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery-0.10 ± 0.42-5.42 ± 0.33
SecondaryChange From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery

The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery-0.06 ± 0.50-6.01 ± 0.50-7.45 ± 0.49
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation

An Adverse Event (AE) was defined as any untoward medical occurrence that did not necessarily have to have a causal relationship with the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of drug until 84 days following the last administration of drug. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.

Time frame:
Baseline up to 84 days after last dose of study drug (up to 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation
ParticipantsPlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Any TEAE138134125
Any treatment emergent SAE16128
Any TEAE leading to death010
TEAE leading to treatment discontinuation1726
SecondaryChange From Baseline at Week 24 in European Quality of Life 5 Dimension Scale (EQ-5D) Visual Analog Scale Score

The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable). All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 24 in European Quality of Life 5 Dimension Scale (EQ-5D) Visual Analog Scale Score
score on a scalePlaceboDupilumab 300 mg (24 Weeks Pooled Arm)
Change From Baseline at Week 24 in European Quality of Life 5 Dimension Scale (EQ-5D) Visual Analog Scale Score3.91 ± 1.5010.83 ± 1.16
SecondaryChange From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score

The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score
score on a scalePlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Change From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score1.38 ± 1.6011.98 ± 1.6313.14 ± 1.62
SecondaryFunctional Dupilumab Concentration in Serum
Time frame:
Baseline, Week 2, Week 4, Week 16, Week 24, Week 40, End of treatment (Week 52), End of study (Week 64)
Reported as:
Mean · nanogram/milliliter
Functional Dupilumab Concentration in Serum
nanogram/milliliterDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Baseline0.00 ± 0.000.00 ± 0.00
Week 221545.79 ± 9120.3622285.67 ± 8459.01
Week 433760.62 ± 16419.7237326.31 ± 14226.12
Week 1670503.07 ± 31234.8674382.04 ± 33118.68
Week 2475929.41 ± 35466.0079890.06 ± 35361.97
Week 4021052.06 ± 18588.6880526.37 ± 34048.41
Week 5217276.13 ± 16353.2075872.58 ± 34127.85
Week 6453.60 ± 160.53851.30 ± 2682.21
SecondaryNumber of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA)

ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as a positive response in the ADA assay post first dose, when baseline results are negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that is greater-than or equal to 4-fold over baseline titer levels, when baseline results are positive.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA)
ParticipantsPlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
With treatment-emergent ADA6188
With treatment-boosted ADA100

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to 64 weeks regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/150 (0%)16/150 (10.7%)111/150 (74%)
Dupilumab 300 mg q2w Then q4w1/148 (0.7%)12/148 (8.1%)95/148 (64.2%)
Dupilumab 300 mg q2w0/149 (0%)8/149 (5.4%)90/149 (60.4%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventPlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
Nasal PolypsRespiratory, thoracic and mediastinal disorders3/1501/1480/149
Facial Bones FractureInjury, poisoning and procedural complications2/1500/1480/149
Abdominal Pain UpperGastrointestinal disorders0/1501/1480/149
PancreatitisGastrointestinal disorders0/1501/1480/149
PyrexiaGeneral disorders0/1501/1480/149
Eosinophilic Granulomatosis With PolyangiitisImmune system disorders0/1501/1480/149
Corneal AbscessInfections and infestations0/1501/1480/149
DiverticulitisInfections and infestations0/1501/1480/149
PneumoniaInfections and infestations0/1501/1480/149
FallInjury, poisoning and procedural complications0/1501/1480/149
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlaceboDupilumab 300 mg q2w Then q4wDupilumab 300 mg q2w
NasopharyngitisInfections and infestations38/15031/14833/149
Nasal PolypsRespiratory, thoracic and mediastinal disorders26/15020/1489/149
Upper Respiratory Tract InfectionInfections and infestations20/1508/14810/149
AsthmaRespiratory, thoracic and mediastinal disorders20/15015/1488/149
EpistaxisRespiratory, thoracic and mediastinal disorders20/1508/14813/149
HeadacheNervous system disorders18/15017/14814/149
SinusitisInfections and infestations17/15014/1489/149
Acute SinusitisInfections and infestations16/1505/1485/149
Accidental OverdoseInjury, poisoning and procedural complications11/15012/1485/149
ArthralgiaMusculoskeletal and connective tissue disorders2/15012/1487/149

Baseline characteristics

Analysis was performed on randomized population which included any participant who was allocated to a randomized treatment regardless of whether any treatment kit was used.

Age, Continuous
Age, Continuous(years)PlaceboDupilumab 300 mg q2w Then q4wDupilumab 300mg q2wTotal
Mean51.67 ± 12.6652.28 ± 12.8751.91 ± 11.8851.95 ± 12.45
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumab 300 mg q2w Then q4wDupilumab 300mg q2wTotal
Female585853169
Male958797279
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDupilumab 300 mg q2w Then q4wDupilumab 300mg q2wTotal
Hispanic or Latino404250132
Not Hispanic or Latino113102100315
Unknown or Not Reported0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDupilumab 300 mg q2w Then q4wDupilumab 300mg q2wTotal
Caucasian/White128120124372
Black/of African descent3227
Asian/Oriental18191754
American Indian or Alaska Native32712
Native Hawaiian or Other Pacific Islander0101
Multiple1102
Nasal Congestion/Obstruction (NC) Symptom Severity Score
Nasal Congestion/Obstruction (NC) Symptom Severity Score(score on a scale)PlaceboDupilumab 300 mg q2w Then q4wDupilumab 300mg q2wTotal
Mean2.38 ± 0.542.44 ± 0.592.48 ± 0.622.43 ± 0.59
Nasal Polyp Score (NPS)
Nasal Polyp Score (NPS)(score on a scale)PlaceboDupilumab 300 mg q2w Then q4wDupilumab 300mg q2wTotal
Mean5.96 ± 1.216.29 ± 1.206.07 ± 1.226.10 ± 1.21
08

Study locations

123 sites
  • Investigational Site Number 8400019
    Birmingham, Alabama 35209, United States
  • Investigational Site Number 8400011
    Fresno, California 93720, United States
  • Investigational Site Number 8400008
    Huntington Beach, California 92647, United States
  • Investigational Site Number 8400004
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number 8400012
    Walnut Creek, California 94598, United States
  • Investigational Site Number 8400017
    Colorado Springs, Colorado 80909, United States
  • Investigational Site Number 8400006
    Denver, Colorado 80230, United States
  • Investigational Site Number 8400022
    New Haven, Connecticut 06519, United States
  • Investigational Site Number 8400002
    Louisville, Kentucky 40207, United States
  • Investigational Site Number 8400021
    Boston, Massachusetts 02114, United States
  • Investigational Site Number 8400014
    Kansas City, Missouri 64114, United States
  • Investigational Site Number 8400024
    Bronx, New York 10461, United States
  • Investigational Site Number 8400016
    North Charleston, North Carolina 29420, United States
  • Investigational Site Number 8400013
    Bethlehem, Pennsylvania 18017, United States
  • Investigational Site Number 8400005
    Philadelphia, Pennsylvania 19104, United States
  • Investigational Site Number 8400003
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site Number 8400009
    Salt Lake City, Utah 84132, United States
  • Investigational Site Number 8400010
    Bellevue, Washington 98225, United States
  • Investigational Site Number 8400007
    Milwaukee, Wisconsin 53219, United States
  • Investigational Site Number 0320006
    Buenos Aires, B1602DQD, Argentina
  • Investigational Site Number 0320004
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number 0320005
    Caba, C1414AIF, Argentina
  • Investigational Site Number 0320001
    Caba, C1425BEN, Argentina
  • Investigational Site Number 0320007
    Caba, C1426ABP, Argentina
  • Investigational Site Number 0320003
    Mendoza, 5500, Argentina
  • Investigational Site Number 0320008
    Rosario, S2000DBS, Argentina
  • Investigational Site Number 0320002
    San Miguel De Tucumán, T4000IAR, Argentina
  • Investigational Site Number 0360002
    Clayton, 3168, Australia
  • Investigational Site Number 0360004
    Herston, 4029, Australia
  • Investigational Site Number 0360005
    Murdoch, 6150, Australia
  • Investigational Site Number 0360001
    Parkville, 3050, Australia
  • Investigational Site Number 0360003
    Prahran, 3004, Australia
  • Investigational Site Number 0560003
    Bruxelles, 1200, Belgium
  • Investigational Site Number 0560001
    Gent, 9000, Belgium
  • Investigational Site Number 0560002
    Leuven, 3500, Belgium
  • Investigational Site Number 1240007
    Kingston, K7L 2V7, Canada
  • Investigational Site Number 1240002
    Montreal, H2W 1T8, Canada
  • Investigational Site Number 1240006
    Montreal, H4A 3J1, Canada
  • Investigational Site Number 1240005
    Ottawa, K1G 6C6, Canada
  • Investigational Site Number 1240003
    Quebec, G1V 4G5, Canada
  • Investigational Site Number 1240004
    Quebec, G1V 4W2, Canada
  • Investigational Site Number 1240008
    Trois-Rivieres, G8T 7A1, Canada
  • Investigational Site Number 1240001
    Vancouver, V5Z 1M9, Canada
  • Investigational Site Number 1520009
    Quillota, 2260877, Chile
  • Investigational Site Number 1520010
    San Fernando, Chile
  • Investigational Site Number 1520005
    Santiago, 7500010, Chile
  • Investigational Site Number 1520011
    Santiago, 7500571, Chile
  • Investigational Site Number 1520008
    Santiago, 7500692, Chile
  • Investigational Site Number 1520006
    Santiago, 7980378, Chile
  • Investigational Site Number 1520001
    Santiago, 8207257, Chile
  • Investigational Site Number 1520014
    Santiago, 8910131, Chile
  • Investigational Site Number 1520003
    Talca, Chile
  • Investigational Site Number 1520007
    Viña Del Mar, Chile
  • Investigational Site Number 3760001
    Hadera, 38100, Israel
  • Investigational Site Number 3760003
    Nahariya, 22100, Israel
  • Investigational Site Number 3760002
    Petah-Tikva, 49100, Israel
  • Investigational Site Number 3760005
    Rehovot, 76100, Israel
  • Investigational Site Number 3760004
    Tel Hashomer, 52621, Israel
  • Investigational Site Number 3920004
    Bunkyo-Ku, Japan
  • Investigational Site Number 3920009
    Bunkyo-Ku, Japan
  • Investigational Site Number 3920026
    Bunkyo-Ku, Japan
  • Investigational Site Number 3920006
    Chiyoda-Ku, Japan
  • Investigational Site Number 3920024
    Fukuoka-Shi, Japan
  • Investigational Site Number 3920010
    Hirakata-Shi, Japan
  • Investigational Site Number 3920011
    Hiroshima-Shi, Japan
  • Investigational Site Number 3920007
    Iida-Shi, Japan
  • Investigational Site Number 3920015
    Inzai-Shi, Japan
  • Investigational Site Number 3920012
    Itabashi-Ku, Japan
  • Investigational Site Number 3920014
    Izumisano-Shi, Japan
  • Investigational Site Number 3920016
    Kawasaki-Shi, Japan
  • Investigational Site Number 3920020
    Kitakyushu-Shi, Japan
  • Investigational Site Number 3920027
    Kitakyushu-Shi, Japan
  • Investigational Site Number 3920002
    Kumamoto-Shi, Japan
  • Investigational Site Number 3920021
    Kumamoto-Shi, Japan
  • Investigational Site Number 3920003
    Kyoto-Shi, Japan
  • Investigational Site Number 3920023
    Meguro-Ku, Japan
  • Investigational Site Number 3920013
    Moriguchi-Shi, Japan
  • Investigational Site Number 3920025
    Okayama-Shi, Japan
  • Investigational Site Number 3920018
    Osaka-Shi, Japan
  • Investigational Site Number 3920017
    Ota-Ku, Japan
  • Investigational Site Number 3920005
    Sendai-Shi, Japan
  • Investigational Site Number 3920022
    Sendai-Shi, Japan
  • Investigational Site Number 3920001
    Shimonoseki-Shi, Japan
  • Investigational Site Number 3920029
    Shinagawa-Ku, Japan
  • Investigational Site Number 3920030
    Shinjyuku-Ku, Japan
  • Investigational Site Number 3920028
    Takatsuki-Shi, Japan
  • Investigational Site Number 3920019
    Yoshida-Gun, Japan
  • Investigational Site Number 4840001
    Chihuahua, 31000, Mexico
  • Investigational Site Number 4840005
    Chihuahua, 31200, Mexico
  • Investigational Site Number 4840004
    Durango, 34080, Mexico
  • Investigational Site Number 4840002
    Guadalajara, 44100, Mexico
  • Investigational Site Number 4840003
    Monterrey, 64460, Mexico
  • Investigational Site Number 6200004
    Aveiro, 3810-501, Portugal
  • Investigational Site Number 6200006
    Guimarães, 4810-061, Portugal
  • Investigational Site Number 6200002
    Lisboa, 1349-019, Portugal
  • Investigational Site Number 6200007
    Matosinhos, 4460-188, Portugal
  • Investigational Site Number 6200001
    Porto, 4099-001, Portugal
  • Investigational Site Number 6200005
    Viana Do Castelo, 4901-858, Portugal
  • Investigational Site Number 6430006
    Moscow, 123182, Russian Federation
  • Investigational Site Number 6430003
    Odintsovo, 143005, Russian Federation

Showing the first 100 of 123 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Peters AT, Soler ZM, Kern RC, Heffler E, Maspero JF, Crampette L, Fujieda S, Lane AP, Zhang H, Nash S, Khan AH, Siddiqui S, Jacob-Nara JA, Rowe P, Deniz Y. Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials. Clin Exp Allergy. 2022 Sep;52(9):1105-1109. doi: 10.1111/cea.14194. Epub 2022 Jul 12. No abstract available. PubMed 35775319 ↗
  • Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28. PubMed 35636689 ↗
  • Bachert C, Peters AT, Heffler E, Han JK, Olze H, Pfaar O, Chuang CC, Rout R, Attre R, Goga L, Jacob-Nara JA, Rowe PJ, Deniz Y, Chen Z, Kamat S, Siddiqui S. Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies. Clin Exp Allergy. 2022 Feb;52(2):244-249. doi: 10.1111/cea.14051. No abstract available. PubMed 35092110 ↗
  • Lee SE, Hopkins C, Mullol J, Msihid J, Guillemin I, Amin N, Mannent LP, Li Y, Siddiqui S, Chuang CC, Kamat S, Khan AH. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies. Allergy. 2022 Jul;77(7):2211-2221. doi: 10.1111/all.15222. Epub 2022 Feb 1. PubMed 35034364 ↗
  • Bachert C, Corren J, Lee SE, Zhang H, Harel S, Cunoosamy D, Khan AH, Jacob-Nara JA, Siddiqui S, Nash S, Rowe PJ, Deniz Y. Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials. Int Forum Allergy Rhinol. 2022 Sep;12(9):1191-1195. doi: 10.1002/alr.22964. Epub 2022 Jan 31. No abstract available. PubMed 34970860 ↗
  • Geng B, Bachert C, Busse WW, Gevaert P, Lee SE, Niederman MS, Chen Z, Lu X, Khokhar FA, Kapoor U, Pandit-Abid N, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. J Allergy Clin Immunol Pract. 2022 Mar;10(3):732-741. doi: 10.1016/j.jaip.2021.12.006. Epub 2021 Dec 22. PubMed 34954123 ↗
  • Hellings PW, Peters AT, Chaker AM, Heffler E, Zhang H, Praestgaard A, Nash S, Khan AH, Siddiqui S, Jacob-Nara JA, Rowe PJ, Deniz Y. Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022 Jul;12(7):958-962. doi: 10.1002/alr.22944. Epub 2022 Jan 23. No abstract available. PubMed 34911163 ↗
  • Han JK, Bachert C, Lee SE, Hopkins C, Heffler E, Hellings PW, Peters AT, Kamat S, Whalley D, Qin S, Nelson L, Siddiqui S, Khan AH, Li Y, Mannent LP, Guillemin I, Chuang CC. Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis. Laryngoscope. 2022 Feb;132(2):265-271. doi: 10.1002/lary.29888. Epub 2021 Dec 1. PubMed 34850966 ↗
  • Chuang CC, Guillemin I, Bachert C, Lee SE, Hellings PW, Fokkens WJ, Duverger N, Fan C, Daizadeh N, Amin N, Mannent LP, Khan AH, Kamat S. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds. Laryngoscope. 2022 Feb;132(2):259-264. doi: 10.1002/lary.29911. Epub 2021 Nov 24. PubMed 34817082 ↗
  • Mullol J, Laidlaw TM, Bachert C, Mannent LP, Canonica GW, Han JK, Maspero JF, Picado C, Daizadeh N, Ortiz B, Li Y, Ruddy M, Laws E, Amin N. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. Allergy. 2022 Apr;77(4):1231-1244. doi: 10.1111/all.15067. Epub 2021 Oct 1. PubMed 34459002 ↗
  • Khan AH, Reaney M, Guillemin I, Nelson L, Qin S, Kamat S, Mannent L, Amin N, Whalley D, Hopkins C. Development of Sinonasal Outcome Test (SNOT-22) Domains in Chronic Rhinosinusitis With Nasal Polyps. Laryngoscope. 2022 May;132(5):933-941. doi: 10.1002/lary.29766. Epub 2021 Aug 26. PubMed 34437720 ↗
  • Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amin N, Ardeleanu M, Radin A, Shumel B, Ruddy M, Patel N, Pirozzi G, Mannent L, Graham NMH. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021 Jul;51(7):915-931. doi: 10.1111/cea.13954. Epub 2021 Jun 26. PubMed 34037993 ↗
  • Fujieda S, Matsune S, Takeno S, Ohta N, Asako M, Bachert C, Inoue T, Takahashi Y, Fujita H, Deniz Y, Rowe P, Ortiz B, Li Y, Mannent LP. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. Allergy. 2022 Jan;77(1):186-196. doi: 10.1111/all.14906. Epub 2021 Jun 4. PubMed 33993501 ↗
  • Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, Hopkins C, Burton MJ. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013513. doi: 10.1002/14651858.CD013513.pub3. PubMed 33710614 ↗
  • Hopkins C, Wagenmann M, Bachert C, Desrosiers M, Han JK, Hellings PW, Lee SE, Msihid J, Radwan A, Rowe P, Amin N, Deniz Y, Ortiz B, Mannent LP, Rout R. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2021 Jul;11(7):1087-1101. doi: 10.1002/alr.22780. Epub 2021 Feb 21. PubMed 33611847 ↗
  • Peters AT, Han JK, Hellings P, Heffler E, Gevaert P, Bachert C, Xu Y, Chuang CC, Neupane B, Msihid J, Mannent LP, Guyot P, Kamat S. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2021 Jun;9(6):2461-2471.e5. doi: 10.1016/j.jaip.2021.01.031. Epub 2021 Feb 4. PubMed 33548517 ↗
  • Laidlaw TM, Bachert C, Amin N, Desrosiers M, Hellings PW, Mullol J, Maspero JF, Gevaert P, Zhang M, Mao X, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Staudinger H, Mannent LP. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol. 2021 May;126(5):584-592.e1. doi: 10.1016/j.anai.2021.01.012. Epub 2021 Jan 16. PubMed 33465455 ↗
  • Fujieda S, Matsune S, Takeno S, Asako M, Takeuchi M, Fujita H, Takahashi Y, Amin N, Deniz Y, Rowe P, Mannent L. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan. Laryngoscope. 2021 Jun;131(6):E1770-E1777. doi: 10.1002/lary.29230. Epub 2020 Nov 23. PubMed 33226139 ↗
  • Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19. Erratum In: Lancet. 2019 Nov 2;394(10209):1618. doi: 10.1016/S0140-6736(19)32218-4. PubMed 31543428 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Not available for request

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Aug 2018, 20 months.

Results were first posted in Oct 2019, 1 year 1 month after primary completion.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2016
First posted
Sep 13, 2016
StartActual
Nov 28, 2016
Primary completionActual
Aug 27, 2018
CompletionActual
Nov 16, 2018
Results first posted
Oct 23, 2019
Last update
Oct 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02898454
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 13, 2016
Start date
Nov 28, 2016
Primary completion
Aug 27, 2018
Completion
Nov 16, 2018
Results posted
Oct 23, 2019
Last update
Oct 23, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion